StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals cash

Cash and short-term investments held at the end of each period.

Provectus Biopharmaceuticals's cash was $1.16M at Jun 30, 2026. For fiscal 2025 it was $251.29K, down 18.3% from the year before. Over ten years it grew -33.2% a year on average. The highest annual figure on record is $17.39M in fiscal 2014.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$251.29K-18.3%
FY2024Dec 31, 2024$307.44K+301.5%
FY2023Dec 31, 2023$76.58K+254.4%
FY2022Dec 31, 2022$21.61K-96.8%
FY2021Dec 31, 2021$682.98K+602.4%
FY2020Dec 31, 2020$97.23K-83.5%
FY2019Dec 31, 2019$590.71K+1058.6%
FY2018Dec 31, 2018$50.99K-51.7%
FY2017Dec 31, 2017$105.50K-90.9%
FY2016Dec 31, 2016$1.17M-91.8%
FY2015Dec 31, 2015$14.18M-18.5%
FY2014Dec 31, 2014$17.39M+10.8%
FY2013Dec 31, 2013$15.70M+1184.8%
FY2012Dec 31, 2012$1.22M-84.1%
FY2011Dec 31, 2011$7.71M-4.7%
FY2010Dec 31, 2010$8.09M+149.8%
FY2009Dec 31, 2009$3.24M+15.8%
FY2008Dec 31, 2008$2.80M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.16M+199.8%
Q1 FY2026Mar 31, 2026$223.88K-42.7%
Q4 FY2025Dec 31, 2025$251.29K-18.3%
Q3 FY2025Sep 30, 2025$72.48K-61.3%
Q2 FY2025Jun 30, 2025$385.93K+1204.7%
Q1 FY2025Mar 31, 2025$390.44K+2064.9%
Q4 FY2024Dec 31, 2024$307.44K+301.5%
Q3 FY2024Sep 30, 2024$187.46K-49.0%
Q2 FY2024Jun 30, 2024$29.58K-83.2%
Q1 FY2024Mar 31, 2024$18.04K-47.2%
Q4 FY2023Dec 31, 2023$76.58K+254.4%
Q3 FY2023Sep 30, 2023$367.25K+447.9%
Q2 FY2023Jun 30, 2023$176.01K+108.9%
Q1 FY2023Mar 31, 2023$34.15K-80.3%
Q4 FY2022Dec 31, 2022$21.61K-96.8%
Q3 FY2022Sep 30, 2022$67.03K-73.6%
Q2 FY2022Jun 30, 2022$84.27K+77.8%
Q1 FY2022Mar 31, 2022$173.61K-50.4%
Q4 FY2021Dec 31, 2021$682.98K+602.4%
Q3 FY2021Sep 30, 2021$254.08K-74.2%
Q2 FY2021Jun 30, 2021$47.41K-96.8%
Q1 FY2021Mar 31, 2021$349.77K+63.6%
Q4 FY2020Dec 31, 2020$97.23K-83.5%
Q3 FY2020Sep 30, 2020$986.52K+126.9%
Q2 FY2020Jun 30, 2020$1.48M+12.0%
Q1 FY2020Mar 31, 2020$213.74K-87.9%
Q4 FY2019Dec 31, 2019$590.71K+1058.6%
Q3 FY2019Sep 30, 2019$434.79K+87.5%
Q2 FY2019Jun 30, 2019$1.32M+913.7%
Q1 FY2019Mar 31, 2019$1.77M+624.3%
Q4 FY2018Dec 31, 2018$50.99K-51.7%
Q3 FY2018Sep 30, 2018$231.92K+11.3%
Q2 FY2018Jun 30, 2018$130.63K-88.4%
Q1 FY2018Mar 31, 2018$244.10K-44.1%
Q4 FY2017Dec 31, 2017$105.50K-90.9%
Q3 FY2017Sep 30, 2017$208.28K-96.0%
Q2 FY2017Jun 30, 2017$1.13M–
Q1 FY2017Mar 31, 2017$436.95K–
Q4 FY2016Dec 31, 2016$1.17M–
Q3 FY2016Sep 30, 2016$5.18M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?